5-(1-((R)-6-(tert-butoxy)-5-(3-((S)-1,5-di-tert-butoxy-1,5-dioxopentan-2-yl)ureido)-6-oxohexyl)-1H-1,2,3-triazol-4-yl)pentanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 5-(1-((R)-6-(tert-butoxy)-5-(3-((S)-1,5-di-tert-butoxy-1,5-dioxopentan-2-yl)ureido)-6-oxohexyl)-1H-1,2,3-triazol-4-yl)pentanoic acid
• 英文别名: 5-[1-[(5R)-5-[[(2S)-1,5-bis[(2-methylpropan-2-yl)oxy]-1,5-dioxopentan-2-yl]carbamoylamino]-6-[(2-methylpropan-2-yl)oxy]-6-oxohexyl]triazol-4-yl]pentanoic acid
• 化学式: C₃₁H₅₃N₅O₉
• 分子量: 639.79
• InChiKey: RHJPCVMCLOMLTF-PKTZIBPZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  45
• 可旋转键数：
  23
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  188
• 氢给体数：
  3
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  6-庚炔酸 、 (S)-di-tert-butyl 2-(3-((S)-6-azido-1-tert-butoxy-1-oxohexan-2-yl)ureido)pentanedioate 在 copper(II) sulfate 、 sodium ascorbate 作用下， 以 水 、 叔丁醇 为溶剂， 反应 0.17h， 生成 5-(1-((R)-6-(tert-butoxy)-5-(3-((S)-1,5-di-tert-butoxy-1,5-dioxopentan-2-yl)ureido)-6-oxohexyl)-1H-1,2,3-triazol-4-yl)pentanoic acid
  参考文献：
  名称：

  [EN] SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER
  [FR] COMPOSÉS SYNTHÉTIQUES MIMÉTIQUES D'ANTICORPS (SYAMS) CIBLANT LE CANCER, NOTTAMENT LE CANCER DE LA PROSTATE

  摘要：

  本发明涉及作为抗体类似物的化合物。这些化合物是具有双功能/多功能的化合物，其中至少含有一个癌细胞结合基团，该基团选择性地结合到前列腺特异性膜抗原（PSMA），以及一个结合到FC受体的基团，该基团调节FC免疫受体，最好是FCγRI受体。根据本发明的化合物选择性地结合到上调PSMA的癌细胞，并通过该相互作用，将化合物的FC受体结合基团置于接近FC受体，最好是FCγRI受体的位置，该受体可以调节（最好是上调）患者对癌细胞的体液反应。通过本发明的化合物的生物作用，包括转移性癌细胞，特别是前列腺癌细胞可以被免疫调控，从而有利地治疗患者的癌症。使用这些化合物治疗癌症和/或减少癌症转移可能性的方法是本发明的其他方面。

  公开号：

  WO2014178878A1

文献信息

• SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER
  申请人：YALE UNIVERSITY

  公开号：US20160082112A1

  公开（公告）日：2016-03-24

  The present invention relates to compounds which function as antibody mimetic compounds. These compounds are bifunctional/multifunctional compounds which contain at least one cancer cell binding moiety which selectively binds to prostate specific membrane antigen (PSMA) and a FC receptor binding moiety which modulates an FC immune receptor, preferably a FcγRI receptor. Compounds according to the present invention bind selectively to cancer cells which upregulate PSMA and through that interaction, place the Fc receptor binding moiety of the compound in proximity to a Fc receptor, preferably a FcγRI receptor, which can modulate (preferably, upregulate) a humoral response in a patient to cancer cells. Through this biological action of the compounds according to the present invention, cancer cells, including metastatic cancer cells, especially prostate cancer cells can be immune regulated, resulting in the favorable therapy of cancer in a patient. Methods of using these compounds to treat cancer and/or reduce the likelihood of metastatis of cancer are additional aspects of the present invention.

  本发明涉及作为抗体模拟化合物的化合物。这些化合物是双功能/多功能化合物，包含至少一个癌细胞结合基团，该基团选择性地结合到前列腺特异性膜抗原（PSMA），以及一个FC受体结合基团，该基团调节FC免疫受体，优选为FcγRI受体。根据本发明的化合物选择性地结合到上调PSMA的癌细胞，并通过这种相互作用，使化合物的Fc受体结合基团靠近FC受体，优选为FcγRI受体，从而可以调节（优选为上调）患者对癌细胞的体液反应。通过本发明化合物的这种生物作用，包括转移性癌细胞，特别是前列腺癌细胞，可以被免疫调节，从而有利于患者的癌症治疗。使用这些化合物治疗癌症和/或减少癌症转移可能性的方法是本发明的其他方面。
• Synthetic antibody mimetic compounds (SYAMS) targeting cancer, especially prostate cancer
  申请人：YALE UNIVERSITY

  公开号：US10117943B2

  公开（公告）日：2018-11-06

  The present invention relates to compounds which function as antibody mimetic compounds. These compounds are bifunctional/multifunctional compounds which contain at least one cancer cell binding moiety which selectively binds to prostate specific membrane antigen (PSMA) and a FC receptor binding moiety which modulates an FC immune receptor, preferably a FcγRI receptor. Compounds according to the present invention bind selectively to cancer cells which upregulate PSMA and through that interaction, place the Fc receptor binding moiety of the compound in proximity to a Fc receptor, preferably a FcγRI receptor, which can modulate (preferably, upregulate) a humoral response in a patient to cancer cells. Through this biological action of the compounds according to the present invention, cancer cells, including metastatic cancer cells, especially prostate cancer cells can be immune regulated, resulting in the favorable therapy of cancer in a patient. Methods of using these compounds to treat cancer and/or reduce the likelihood of metastatis of cancer are additional aspects of the present invention.

  本发明涉及具有抗体模拟功能的化合物。这些化合物是双功能/多功能化合物，至少含有一个选择性结合前列腺特异性膜抗原（PSMA）的癌细胞结合分子和一个调节 FC 免疫受体（最好是 FcγRI 受体）的 FC 受体结合分子。根据本发明的化合物可选择性地与上调 PSMA 的癌细胞结合，并通过这种相互作用，将化合物的 Fc 受体结合分子置于 Fc 受体（最好是 FcγRI 受体）附近，从而调节（最好是上调）患者对癌细胞的体液反应。通过根据本发明的化合物的这种生物作用，癌细胞，包括转移性癌细胞，尤其是前列腺癌细胞可以被免疫调节，从而有利于患者的癌症治疗。使用这些化合物治疗癌症和/或降低癌症转移可能性的方法是本发明的其他方面。
• Synthetic antibody mimetic compounds (SyAMs) targeting cancer, especially prostate cancer
  申请人：YALE UNIVERSITY

  公开号：US10912836B2

  公开（公告）日：2021-02-09

  The present invention relates to compounds which function as antibody mimetic compounds. These compounds are bifunctional/multifunctional compounds which contain at least one cancer cell binding moiety which selectively binds to prostate specific membrane antigen (PSMA) and a FC receptor binding moiety which modulates an FC immune receptor, preferably a FcγRI receptor. Compounds according to the present invention bind selectively to cancer cells which upregulate PSMA and through that interaction, place the Fc receptor binding moiety of the compound in proximity to a Fc receptor, preferably a FcγRI receptor, which can modulate (preferably, upregulate) a humoral response in a patient to cancer cells. Through this biological action of the compounds according to the present invention, cancer cells, including metastatic cancer cells, especially prostate cancer cells can be immune regulated, resulting in the favorable therapy of cancer in a patient. Methods of using these compounds to treat cancer and/or reduce the likelihood of metastasis of cancer are additional aspects of the present invention.

  本发明涉及具有抗体模拟功能的化合物。这些化合物是双功能/多功能化合物，至少含有一个选择性结合前列腺特异性膜抗原（PSMA）的癌细胞结合分子和一个调节 FC 免疫受体（最好是 FcγRI 受体）的 FC 受体结合分子。根据本发明的化合物可选择性地与上调 PSMA 的癌细胞结合，并通过这种相互作用，将化合物的 Fc 受体结合分子置于 Fc 受体（最好是 FcγRI 受体）附近，从而调节（最好是上调）患者对癌细胞的体液反应。通过根据本发明的化合物的这种生物作用，癌细胞，包括转移性癌细胞，尤其是前列腺癌细胞可以被免疫调节，从而有利于患者的癌症治疗。使用这些化合物治疗癌症和/或降低癌症转移可能性的方法是本发明的其他方面。
• [EN] SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER<br/>[FR] COMPOSÉS SYNTHÉTIQUES MIMÉTIQUES D'ANTICORPS (SYAMS) CIBLANT LE CANCER, NOTTAMENT LE CANCER DE LA PROSTATE
  申请人：UNIV YALE

  公开号：WO2014178878A1

  公开（公告）日：2014-11-06

  The present invention relates to compounds which function as antibody mimetic compounds. These compounds are bifunctional/multifunctional compounds which contain at least one cancer cell binding moiety which selectively binds to prostate specific membrane antigen (PSMA) and a FC receptor binding moiety which modulates an FC immune receptor, preferably a FcγRI receptor. Compounds according to the present invention bind selectively to cancer cells which upregulate PSMA and through that interaction, place the Fc receptor binding moiety of the compound in proximity to a Fc receptor, preferably a FcγRI receptor, which can modulate (preferably, upregulate) a humoral response in a patient to cancer cells. Through this biological action of the compounds according to the present invention, cancer cells, including metastatic cancer cells, especially prostate cancer cells can be immune regulated, resulting in the favorable therapy of cancer in a patient. Methods of using these compounds to treat cancer and/or reduce the likelihood of metastatis of cancer are additional aspects of the present invention.

  本发明涉及作为抗体类似物的化合物。这些化合物是具有双功能/多功能的化合物，其中至少含有一个癌细胞结合基团，该基团选择性地结合到前列腺特异性膜抗原（PSMA），以及一个结合到FC受体的基团，该基团调节FC免疫受体，最好是FCγRI受体。根据本发明的化合物选择性地结合到上调PSMA的癌细胞，并通过该相互作用，将化合物的FC受体结合基团置于接近FC受体，最好是FCγRI受体的位置，该受体可以调节（最好是上调）患者对癌细胞的体液反应。通过本发明的化合物的生物作用，包括转移性癌细胞，特别是前列腺癌细胞可以被免疫调控，从而有利地治疗患者的癌症。使用这些化合物治疗癌症和/或减少癌症转移可能性的方法是本发明的其他方面。